RESEARCH





Rachael Muinde¹, Kevin Owuor¹, Jones Mutiso¹, Jonathan Mwangi² and Paul Wekesa^{1*}

Abstract

Background Routine program data indicates positivity rates under 2% from HIV testing services (HTS) at sites supported by Centre for Health Solutions-Kenya in Central Kenya. Achieving the UNAIDS 95:95:95 goals requires continuous identification of people living with HIV in an environment of diminishing resources. We assessed non-clinical and clinical characteristics of persons who tested HIV-positive aimed at improving the process of HTS through Provider-Initiated HIV Testing & Counseling (PITC).

Methods We conducted a retrospective analysis of routine PITC program data collected between October 2018 and September 2019 from six health facilities located in three counties in central Kenya. Stratification was based on county and facility volume. A multivariable logistic regression model, clustered adjusted for facility using robust standard errors, was used to determine predictors of a positive HIV result.

Results The total sample was 80,693 with an overall positivity rate of 1.2%. Most, (65.5%), were female and 6.1% were < 15 years. Most clients, 55,464 (68.7%), had previously tested for HIV. Client characteristics associated with a higher odds of positivity on multivariable analysis included: being female (adjusted odds ratio [aOR] 1.27, 95% confidence interval [CI] (1.03–1.57); adults 15 years and above compared to children < 15 years, divorced and married polygamous compared to married monogamous [aOR 3.98, 95% CI (2.12–7.29) and aOR 2.41 95% CI (1.48–3.94) respectively]; clients testing for the first time compared to repeat testers in less than 12 months [aOR 1.39, 95% CI (1.27–1.51)]. Similarly, repeat testers in more than 12 months compared to repeat testers in less than 12 months [aOR 1.90, 95% CI (1.55–2.32)]; presumptive TB clients compared to those without signs of TB [aOR 16.25, 95% CI (10.63–24.84)]. Clients tested at inpatient departments (IPD) were more likely to get a positive HIV result compared to those tested at outpatient departments (OPD), and other departments.

Conclusions The study findings highlight client characteristics such as age, marital status, HIV test entry point, first-time test, repeat test after 12 months, and TB status as factors that could influence PITC results and could be used to develop a screening tool to target eligible clients for HTS in low HIV prevalence settings.

Keywords HIV testing, Positivity, Provider Initiated Testing, Client characteristics

*Correspondence: Paul Wekesa pwekesa@chskenya.org Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Introduction

An estimated 1.5 million Kenyans are living with HIV of whom 79.5% are aware of their status [1]. The 2018 Kenya HIV prevalence survey (KENPHIA), estimated a national HIV prevalence of 4.9% among adults and 0.7% among children. In three counties of central Kenya, HIV prevalence was estimated at 4.2% in Murang'a County, 2.2% in Nyandarua, and 5.1% in Nyeri County [1]. Compared to the high HIV burden regions such as Homa Bay County with a prevalence rate of 19.6%, these are low HIV-burden counties and also categorized as middle antiretroviral treatment (ART) coverage counties ranging between 70 to 79% [2]. Routine program data indicates continued low positivity rates from HIV testing services (HTS) with the three counties reporting positivity rates below 2% (male 1.8% and female 1.5%). In 2021, the highest positivity was reported among adults above 25 years (2%) and children aged 0 to 4 years (1.4%) [3].

Achieving the UNAIDS first and second 95 goals requires identifying people living with HIV (PLHIV) and linking them to treatment [4]. Getting to the 95% target remains an uphill task as factors associated with HIV infection continue to change and therefore the need to continuously improve our understanding of the HIV epidemic by region and population. These constant changes suggest the need to continually review program implementation strategies for HTS approaches toward meeting the UNAIDS goals [5]. To this end, the United States President's Emergency Fund for AIDS Relief (PEPFAR) Country Operation Plan 21 required implementing partners to optimize the limited resources by adopting efficient interventions for HIV case identification. Self-test, social network strategies (SNS), and assisted partner notification services (aPNS) are recommended as efficient HTS approaches in Kenya [2, 6]. The 2020 PEPFAR report recognized the need to advance provider-initiated testing and counseling (PITC) as a strategy that contributes the highest number of HIV positives identified compared to other HTS modalities and remains one of the least costly case-finding strategies available [7]. The WHO HIV testing guidelines of 2019 also recommend targeted HIV testing through the use of a symptom screening approach in low HIV burden settings with a national HIV prevalence of below 5% [8].

Research evidence suggests that the implementation of risk prediction algorithms based on patient characteristics could be used to strengthen risk screening and improve case identification and thus introduce moderate efficiencies to HIV testing services offered in health facilities [9]. The 2016 Kenya HIV testing services guidelines which recommended a routine opt-out PITC approach also provided generalized categories of high-risk persons to be prioritized for a test. The national program further proposed the integration of HTS in all service delivery points for national implementation [10]. However, to achieve efficiency in PITC there is a need for deeper analysis to further understand program outcomes based on non-routine parameters and their impact in a subnational context. Since 2017, the Centre for Health Solutions – Kenya (CHS) has implemented aPNS in central Kenya alongside other effective strategies that continue to yield good results measured by the number needed to test to get one HIV-positive case. The program data however shows that PITC contributes over 60% of cases identified in the region. Our study aimed to describe the demographic and clinical characteristics of persons who tested HIV positive to improve the efficiency of HTS to test less and identify more through PITC in Murang'a, Nyandarua, and Nyeri counties of central Kenya.

Study methods

Study population

The study population was all persons tested for HIV through routine provider-initiated testing and counselling interventions. Persons who tested through community testing or partner notification services were excluded from the analysis.

Study design and setting

This was a cross-sectional retrospective study utilizing routine HTS data from October 2018 to September 2019. Six facilities located across 3 counties in central Kenya including Murang'a (Population 1,056,640; HIV prevalence 3%, ART coverage 91%), Nyandarua (Population 638,289; HIV prevalence 2.2%, ART coverage 90%), and Nyeri counties (Population 759,164; HIV prevalence 5.1%, ART coverage 91%) were included in the study [1, 11]. These are Ministry of Health (MOH) owned county referral and primary healthcare hospitals that are supported by the Centre for Health Solutions – Kenya (CHS) to provide HTS services through the Tegemeza Plus project, with funding and technical assistance from the US Centers for Disease Control and Prevention (CDC). Other details, including outcomes of this project setting, have been described elsewhere [12-16]). The facilities were purposively sampled to include a mix of high volume (facility 1-County, facility 2-County, facility 3-County) and low volume (facility 1-County, facility 2- County, facility 3-County). Facility categorization was based on the monthly outpatient department (OPD) workload with high volume being > 10,000 patients seen in a month and low volume being < 10,000 patients seen in a month. A census of all clients was done and included a total of 80,683 clients (35,018 - Murang'a county, 21,909 – Nyandarua county, and 23,756 – Nyeri county).

Data collection and management

Routine data were collected by data officers who abstracted data from the laboratory HIV testing services registers (MOH 362) covering the period between October 2018 to September 2019. The outcome variable was the HIV test result while predictors variables included the date of the HIV test, age, sex, marital status, population type (key population [men who have sex with men (MSM), people who inject drugs (PWID), female sex workers (FSW)] versus general population), department (outpatient department [OPD] vs inpatient department [IPD], integrated management of childhood illnesses (IMCI), others [Medical outpatient clinics for dermatology, dental, diabetes]), new (never tested before) or repeat HIV test (tested in the last 12 months), duration since last HIV test, history of HIV test, history of sexually transmitted infections (STI), tuberculosis (TB) screening results, pre-exposure prophylaxis (PrEP) screening results (answering 'Yes' to any question in the PrEP RAST tool) and GBV screening result (answering 'Yes' to any question in the National GBV screening criteria). Data were entered into a MySQL database and cleaned by data officers, and the final dataset was exported in a Microsoft Excel format for analysis.

Statistical analysis

Routine HIV individual testing data collected at health facilities were used. Descriptive statistics included mean (standard deviation) and counts (proportions). Univariable and multivariable logistic regression models, clustered adjusted for facility-level variations, were used to determine predictors of a positive HIV result. The final multivariable model used was developed using a backward stepwise approach with the probability of inclusion set at 0.20. The univariable and multivariable odds ratios (aOR) and corresponding 95% confidence intervals (CIs) were presented. All the statistical tests were evaluated at the 5% level of significance. All the analyses were done in Stata version 15.1 (StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC.).

Ethical approval

This study was approved by the Kenyatta National Hospital Ethics and Scientific Research Committee. The protocol was also reviewed in accordance with the U.S. Center for Disease Control and Prevention (CDC) human research protection procedures and was determined to be research, but the CDC investigators did not interact with human subjects or have access to identifiable data or specimens for research purposes. We received a waiver of informed consent for the use of retrospective data. All data were kept confidential and only the CHS team had access to identifiable patient data. **Table 1** Description by HIV positive status among clients incentral Kenya, October 2018 to September 2019

Characteristics Negative Positive Total n (%) 79,701 (98.8) 982 (1.2) 80,683 (100.0) County Murang'a 34,600 (43.4) 418 (42.6) 35,018 (43.4) Nyandarua 21,565 (27.1) 344 (35.0) 21,909 (27.2) Nyeri, 23,536 (29.5) 220 (22.4) 23,756 (29.4) Age (category (Years) 35.2 (15.3) 313 (3.4) 4894 (6.1) 15-19 5152 (6.5) 31 (3.2) 5183 (6.4) 20-24 11,069 (13.9) 91 (9.3) 11,160 (13.8) 25-29 11,061 (13.9) 123 (12.5) 11,184 (13.9) 30-34 10,651 (13.4) 163 (16.6) 10,814 (13.4) 35-39 8966 (11.2) 158 (16.1) 9124 (11.3) 340-44 7297 (9.2) 111 (11.3) 7408 (9.2) 45-49 5309 (6.7) 80 (8.1) 5389 (6.7) 50+ 15,335 (19.2) 192 (19.6) 15,527 (19.2) Married Monogamous 49,456 (62.1) 560 (57.0) 50,016 (6.2.0) Divorced		HIV test result																																																																																																																																																																												
n (↔) 0, 982,000,000,000,000,000,000,000,000,000,0	Characteristics	Negative	Positive	Total																																																																																																																																																																										
ConstructMurang'a34,000 (4.34)418 (4.24)3,018 (4.34,0)Nyandarua21,565 (2.71)344 (3.50)21,909 (27.21)Nyandarua23,565 (2.71)344 (3.50)21,909 (27.21)Nyandarua23,565 (2.71)32.01 (2.71)32.01 (2.71)Nyandarua23,565 (2.71)32.01 (2.71)32.01 (2.71)Nyandarua23,565 (2.71)31.32)31.32Syandarua152 (6.51)31.32)11,184 (1.30)2-2410,601 (1.30)12.01 (2.71)11,184 (1.30)2-2911,010 (1.30)12.01 (2.71)12.01 (2.71)30-3410,651 (1.34)16.31 (1.71)70.02 (1.71)40-442300 (2.71)10.11 (2.71)70.02 (1.71)45-92300 (2.71)10.11 (2.71)70.02 (1.71)50-113.33 (1.21)15.27 (1.92)11.12Maried Monogamous19.42 (1.71)20.12 (1.71)Maried Polygamous28.0360.0123.02 (2.71)Maried Polygamous19.12 (1.71)20.12 (1.71)Single21.14 (1.71)12.13 (2.71)Single21.42 (1.71)12.13 (2.71)Single21.42 (1.71)12.13 (2.71)Maried Polygamous19.12 (1.71)12.13 (2.71)Single21.42 (1.71)13.13 (2.71)Single21.42 (1.71)13.13 (2.71)Single21.42 (1.71)13.13 (2.71)Single21.42 (1.71)13.13 (2.71)Single21.42 (1.71)13.13 (2.71)Single21.42	n (%)	79,701 (98.8)	982 (1.2)	80,683 (100.0)																																																																																																																																																																										
Murang'a34,600 (43.4)418 (42.6)35,018 (43.4)Nyandarua21,565 (27.1)344 (35.0)21,909 (27.2)Nyeri,23,536 (29.5)220 (22.4)23,756 (29.4)Age (vears), mean (sd)25,215.4)31.3.135.2 (15.3)Age creating (Years)33.3.135.2 (15.3)31.3.251.83 (6.4)15-195152 (6.5)31.3.251.83 (6.4)30.3.448.94 (6.1)30-3410,651 (13.4)13.16.010.814 (13.4)30.3.430-3410,651 (13.4)13.61.6010.814 (13.4)30-3410,651 (13.4)158 (16.1)91.24 (11.3)40-445309 (67.1)80.8 (1.1)51.85 (27.1)45-49300 (67.1)80.8 (1.1)51.85 (27.1)50+115.35 (19.2)19.21 (1.1)70.016 (62.0)Married Monogamous49.456 (62.1)50.15 (5.27 (19.2)Married Polygamous28.0.3060.6023.40.3)Married Polygamous19.12 (1.3)30.35 (2.5)Separated19.12 (1.3)31.83.2427.805 (35.1)Single27.467 (35.1)31.8 (32.4)27.805 (35.1)Female27.487 (34.5)318 (32.4)27.805 (35.1)Fermale27.487 (34.5)318 (32.4)27.805 (35.1)Fermale27.487 (34.5)318 (32.4)27.805 (35.1)Fermale27.487 (34.5)318 (32.4)36.266 (99.1)Kore14.14.128.13.6)31.41.431.81.6Fermale27.487 (35.5)18.14.2.431.81.6<	County																																																																																																																																																																													
Nyandarua21,565 (27.1)344 (35.0)21,909 (27.2)Nyeri,23,536 (29.5)22.0 (2.4)3,75 (2.5.3)Age (Years), mean (sd)35.2 (15.3)35.2 (15.3)Age creagory (Years)33 (3.4)4894 (6.1)15-195152 (6.5)31 (3.2)11.80 (13.8)20-2410,06 (13.9)91 (9.3)11,06 (13.8)25-2911,06 (13.8)123 (12.5)11,84 (13.9)30-3410,651 (13.4)163 (16.6)10,814 (13.4)35-398966 (11.2)158 (16.1)912.40 (13.8)35-41303 (6.7)80 (8.1)5389 (6.7)35-49309 (6.7)80 (8.1)5389 (6.7)45-495309 (6.7)80 (8.1)5389 (6.7)50+01942 (2.4)93 (9.5)50,16 (62.0)Married Monogamous288 (0.3)60.00234 (0.3)10vorced1942 (2.4)93 (9.5)234 (5.5)Married Polyagamous214 (13.1)228 (13.0)234 (2.3)10vorced1942 (2.4)318 (3.2)7,469 (3.0)10vorced1942 (2.4)11 (1.1)921 (1.2)Single27,478 (34.5)181 (3.2)7,469 (3.0)10vorced1942 (2.4)138 (1.2)14,49310vorced1942 (2.4)14 (1.4)284 (3.6)10vorced1942 (2.4)138 (1.2)14,50310vorced194 (1.2)14 (1.4)284 (3.6)11111194 (2.4)14 (1.4)284 (3.6)11111194 (2.4)14 (1.4)284 (3.6) <td>Murang'a</td> <td>34,600 (43.4)</td> <td>418 (42.6)</td> <td>35,018 (43.4)</td>	Murang'a	34,600 (43.4)	418 (42.6)	35,018 (43.4)																																																																																																																																																																										
Nyeri,23,536 (29.)220 (22.)23,756 (29.)Age (Years), mean (sd)352 (15.3)35.2 (15.3)35.2 (15.3)Age category (Years)313.44894 (6.1)154861 (6.1)31 (3.4)4894 (6.1)15-195152 (6.5)31 (3.2)51.83 (6.4)20-2411,060 (13.3)11.93 (13.4)13.140 (13.8)30-3410,651 (13.4)163 (16.6)10.814 (13.4)35-398966 (11.2)158 (16.1)318 (20.2)40-447297 (9.2)111 (11.3)7408 (9.2)45-495309 (6.7)80 (8.1)5389 (6.7)50 +15,357 (19.2)192 (19.6)50.16 (6.20.0)Married Mongamous194,56 (62.1)60 (50.0)50.16 (62.0)Married Mongamous194,56 (62.1)60.6)524 (13.2)Invired Polygamous192 (12.4)93 (9.5)50.16 (52.0)Joraced1942 (24)93 (9.5)20.4 (3.3)Divorced1942 (24)93 (9.5)20.4 (5.6)Separated1942 (24)93 (9.5)27.469 (3.4)Invired Polygamous1942 (24)93 (9.5)27.469 (3.4)Single27.157 (34.1)318 (3.2)27.657 (34.5)Female70.467 (34.5)818 (3.2)27.653 (3.5)Female70.467 (34.5)818 (3.2)7.605 (3.5)Female70.467 (34.5)814 (1.4)28.13 (3.6)Ipb316 (24.5)14.14128.13 (3.6)Ipc316 (24.5)14.14128.13 (3.6)Ipc16.25 <td>Nyandarua</td> <td>21,565 (27.1)</td> <td>344 (35.0)</td> <td>21,909 (27.2)</td>	Nyandarua	21,565 (27.1)	344 (35.0)	21,909 (27.2)																																																																																																																																																																										
Age (Years), mean (ad)35.2 (15.4)37.3 (13.2)35.2 (15.4)Age (Years), Wears)45.156.3 (3.4)48.44 (A.1)15-1951.52 (6.5)31 (3.2)11.80 (13.8)20-2411.06 (13.3)12.3 (1.2.5)11.84 (13.9)30-3410.65 (11.3)15.81 (6.1)91.44 (1.3.9)35-398966 (11.2)15.81 (6.1)91.44 (1.3.9)40-447297 (9.2)111 (11.3)74.08 (9.2)45-4953.09 (6.7)80.61 (1.2)53.89 (6.7)50+15.35 (19.2)192 (19.0)15.527 (19.2)Married Monogamous24.94 (5.2)50.423.40 (3.3)Married Polygamous22.80 (3.0)60.6)23.40 (3.3)5eparated918 (1.2)11 (1.1)92.49 (3.4)5aparated91.81 (2.1)11 (1.1)92.49 (3.4)5eparated92.41 (6.5)64.67 (3.5)52.878 (6.5.1)Female27.487 (34.5)181 (3.2.4)27.805 (34.5)Female27.487 (34.5)181 (3.2.4)27.805 (34.5)Female50.1111 (1.1)92.69 (3.6)Female79.645 (9.9.1)13.13 (3.2.4)27.805 (34.5)Female79.645 (9.9.1)13.13 (3.2.4)27.805 (34.5)Female79.645 (9.9.1)13.13 (3.2.4)27.805 (34.5)Female79.645 (9.9.1)14.1428.13.6)Female79.645 (9.9.1)14.1428.13.6)Juote14.1428.13.6)14.1428.13.6)Juote13.1214.1428.13.6)<	Nyeri,	23,536 (29.5)	220 (22.4)	23,756 (29.4)																																																																																																																																																																										
Age: category (Years) <15	Age (Years), mean (sd)	35.2 (15.4)	37.3 (13.5)	35.2 (15.3)																																																																																																																																																																										
<154861 (h)33 (3.4)4894 (h)15-195152 (c.5)31 (3.2)5183 (c.4)20-2411,069 (13.9)19.3011,160 (13.8)30-3410,651 (13.4)163 (16.6)10.814 (13.4)35-398966 (11.2)158 (16.1)7408 (92.2)40-447297 (9.2)111 (11.3)7408 (92.2)50+5309 (6.7)80 (8.1)51527 (19.2)Narried Monogamous49.456 (6.21)500 (57.0)50.16 (6.20)Married Polygamous228 (0.3)60.60234 (0.3)Divorced1942 (2.4)93 (9.5)235 (2.5)Separated918 (1.2)11 (1.1)929 (1.2)Single27,157 (34.1)312 (31.8)27,469 (34.0)Separated918 (1.2)13 (13.8)27,469 (34.0)Pourced924 (15.5)664 (67.6)52,878 (65.7)Male72,487 (34.5)318 (32.4)27,805 (34.5)Female22,214 (65.5)664 (67.6)52,878 (65.7)Poulation79,645 (99.9)81 (99.9)80,626 (99.9)IMCI2807 (3.6)14 (1.4)281 (3.6)IPD320 (1.6)16,10032,000IPD320 (1.6)13 (1.6)32,000IPD320 (1.6)15,02032,000IPD320 (1.6)13 (1.6)32,000IPD320 (1.6)15,02032,000IPD320 (1.6)15,02032,000IPD320 (1.6)15,02032,000IPD320 (1.6)32,0003	Age category (Years)																																																																																																																																																																													
15-195152 (c.5)31 (3.2)5183 (6.4)20-2411,069 (13.9)91 (9.3)11,160 (13.8)25-2911,061 (13.9)123 (12.5)11,184 (13.9)30-3410,651 (13.4)163 (16.6)9124 (11.3)40-447297 (9.2)111 (11.3)7408 (9.2)45-495309 (6.7)80 (8.1)5389 (6.7)50+15,353 (19.2)192 (19.6)55,27 (19.2)Married Monogamous49,456 (62.1)560 (57.0)50,016 (62.0)Divorced1942 (2.4)916 (2.1)312 (3.8)27,469 (3.1)Separated1942 (2.4)916 (2.1)312 (3.8)27,469 (3.1)Single228 (0.3)610.5235 (2.5)5Separated1942 (2.4)916 (2.1)92 (1.2)Single221 (65.5)64 (67.6)238 (0.3)Female52,214 (65.5)64 (67.6)52,878 (65.5)Pculation Type, n (%)11 (1.1)92 (1.2)Key Population79,645 (99.9)981 (99.9)80,626 (99.9)Key Population79,645 (99.9)981 (99.9)80,626 (99.9)IMCI286 (3.1)14 (1.4)2881 (3.6)IPD318 (1.2)149 (1.5)4508 (5.6)OPD71,692 (90.0)813 (82.8)72,505 (89.9)Other1214,1923451 (1.6)IPD325 (1.5)149 (1.5)357 (1.6)IPD325 (1.5)149 (1.5)359 (1.6)OPD71,692318 (3.2)359 (1.6)IPD325 (1.5)359	< 15	4861 (6.1)	33 (3.4)	4894 (6.1)																																																																																																																																																																										
20-2411,069 (13.9)91 (9.3)11,160 (13.9)25-2911,061 (13.9)123 (12.5)11,184 (13.9)30-3410,651 (13.4)163 (16.6)9124 (11.3)40-447297 (9.2)111 (11.3)7408 (9.2)45-495309 (6.7)80 (8.1)5389 (6.7)50 +15,335 (19.2)192 (19.6)15,527 (19.2)Married Monogamous49,456 (62.1)560 (57.0)50,016 (62.0)Married Polygamous228 (0.3)6 (0.6)234 (0.3)5eparated1942 (2.4)93 (9.5)2035 (2.5)Separated918 (1.2)11 (1.1)929 (1.2)Single22.21 (46.5)644 (67.6)5.2878 (65.7)Female52.214 (65.5)644 (67.6)5.2878 (65.7)Female79,645 (99.9)981 (99.9)80,626 (99.9)Key Population79,645 (99.9)981 (99.9)80,626 (99.9)Key Population79,645 (99.9)981 (99.9)80,626 (99.9)IMCI2867 (3.6)14 (1.4)2881 (3.6)IPD4359 (5.5)149 (15.2)4508 (5.6)OPD71,692 (90.0)813 (82.8)72,505 (89.9)Other12 months8359 (15.1)142 (13.9)80,471 (78.2)Repeat Test in < 12 months	15–19	5152 (6.5)	31 (3.2)	5183 (6.4)																																																																																																																																																																										
25-2911,061 (13.9)123 (12.5)11,184 (13.9)30-3410,651 (13.4)163 (16.6)10,814 (13.4)35-398966 (11.2)158 (16.1)9124 (11.3)40-447297 (9.2)111 (11.3)7408 (9.2)45-495309 (6.7)80 (8.1)5389 (6.7)50+15,335 (19.2)192 (19.6)15,527 (19.2)Married Monogamous49,456 (62.1)560 (57.0)50,016 (62.0)Married Polygamous228 (0.3)6 (0.6)234 (0.3)Divorced1942 (2.4)93 (9.5)2035 (2.5)Separated918 (1.2)11 (1.1)929 (1.2)Single27,157 (34.1)312 (31.8)27,469 (34.0)Sev_n (%)11 (1.1)929 (1.2)Single27,467 (34.5)318 (32.4)27,805 (34.5)Poulation Type, n (%)52,214 (65.5)664 (67.6)52,878 (65.5)Poulation Type, n (%)11 (1.1)80,626 (99.9)16,01Key Population79,645 (99.9)81 (9.9)80,626 (99.9)Key Population79,645 (99.9)81 (9.9)80,626 (99.9)Key Population79,645 (99.9)140 (1.4)2881 (3.6)Pour166 (1.1)162 (1.1)162 (1.1)IMCI288 (3.6)149 (1.5)848 (3.6)IPD316 (3.2)149 (1.5)450 (5.6)IPD325 (1.5)158 (1.6)817 (10.6)IPD325 (1.5)158 (1.6)817 (10.6)IPD4,457 (3.2)32 (3.3)32,19 (1.3)IPD4,457 (3.2	20–24	11,069 (13.9)	91 (9.3)	11,160 (13.8)																																																																																																																																																																										
30-3410,651 (13,4)163 (16,6)10,814 (13,4)35-398966 (11,2)158 (16,1)9124 (11,3)40-447297 (9,2)111 (11,3)7408 (9,2)45-495309 (6,7)80 (8,1)5389 (6,7)50+15,355 (19,2)192 (19,6)15,527 (19,2)Married Monogamous49,456 (62,1)560 (57,0)50,016 (62,0)Married Polygamous228 (0,3)6 (0,6)234 (0,3)Divorced1942 (2,4)93 (9,5)203 (2,5)Separated194 (2,4)93 (9,5)203 (2,5)Single27,157 (3,4,1)312 (3,8)27,469 (3,4)Sev, n (%)11 (1,1)929 (1,2)Single27,467 (3,4,5)318 (3,2,4)27,805 (3,4,5)Female52,214 (65,5)64 (67,6)52,878 (65,5)Poultion Type, n (%)5555Ceneral Population79,645 (99,9)981 (9,9)8,0626 (99,9)Key Population79,645 (9,9)981 (9,9)8,0626 (99,9)Key Population79,645 (9,9)981 (9,9)8,0626 (99,9)Key Population79,645 (9,9)981 (9,9)8,0626 (99,9)Key Population16,927149 (1,4)2881 (3,6)IPC328 (3,6)149 (1,5)580 (5,6)OPD71,692 (9,0)813 (8,2,8)72,505 (89,9)Other12,902 (1,6)158 (1,6)8517 (1,0,6)IPC12,903 (1,6)158 (1,6)8517 (1,6)IPC12,904 (1,6)158 (1,6)361 (1,6)IPC <t< td=""><td>25–29</td><td>11,061 (13.9)</td><td>123 (12.5)</td><td>11,184 (13.9)</td></t<>	25–29	11,061 (13.9)	123 (12.5)	11,184 (13.9)																																																																																																																																																																										
35-398966 (11.2)158 (16.1)9124 (11.3)40-447297 (9.2)111 (11.3)7408 (9.2)45-495309 (6.7)80 (8.1)5389 (6.7)50 +15,335 (19.2)192 (19.6)15,527 (19.2)Married Monogamous49,456 (62.1)560 (57.0)50,016 (62.0)Married Polygamous228 (0.3)6 (0.6)234 (0.3)Divorced1942 (2.4)93 (9.5)2035 (2.5)Separated918 (1.2)11 (1.1)929 (1.2)Single27,157 (34.1)312 (31.8)27,469 (34.0)Sex, n (%)52,214 (65.5)664 (67.6)52,878 (65.5)Porulation Type, n (%)10.1192 (1.2)General Population79,645 (99.9)981 (99.9)80,626 (99.9)Key Population56 (0.1)1 (0.1)57 (0.1)Porulation Type, n (%)14 (1.4)2881 (3.6)IPD4359 (5.5)149 (15.2)4508 (5.6)OPD71,692 (90.0)813 (82.8)72,505 (89.9)Other783 (1.0)6 (0.6)789 (1.0)Fereat Test in < = 12 months	30-34	10,651 (13.4)	163 (16.6)	10,814 (13.4)																																																																																																																																																																										
40-447297 (9.2)111 (11.3)7408 (9.2)45-495309 (6.7)80 (8.1)5389 (6.7)50 +15,335 (19.2)192 (19.6)15,527 (19.2)Married Status, n (%)560 (57.0)50,016 (62.0)Married Polygamous228 (0.3)6 (0.6)234 (0.3)Divorced1942 (2.4)93 (9.5)2035 (2.5)Separated918 (1.2)11 (1.1)929 (1.2)Single27,157 (34.1)312 (31.8)27,469 (34.0)Sex, n (%)52,214 (65.5)664 (67.6)52,878 (65.5)Female52,214 (65.5)664 (67.6)52,878 (65.5)Population Type, n (%)10.1057 (0.1)Key Population79,645 (99.9)981 (99.9)80,626 (99.9)IMCI2867 (3.6)14 (1.4)2881 (3.6)IPD4359 (5.5)149 (15.2)4508 (5.6)OPD71,692 (90.0)813 (82.8)72,505 (89.9)Other783 (1.0)6 (0.6)789 (1.0)Fereat Test in < = 12 months	35–39	8966 (11.2)	158 (16.1)	9124 (11.3)																																																																																																																																																																										
45-495309 (6.7)80 (8.1)5389 (6.7)50+15,335 (19.2)192 (19.6)15,527 (19.2)Married Status, n (%)560 (57.0)50,016 (62.0)Married Polygamous228 (0.3)6 (0.6)234 (0.3)Divorced1942 (2.4)93 (9.5)2035 (2.5)Separated918 (1.2)11 (1.1)929 (1.2)Single27,157 (34.1)312 (31.8)27,805 (34.5)Female22,214 (65.5)664 (67.6)52,878 (65.5)Female22,214 (65.5)646 (67.6)52,878 (65.5)Population Type, n (%)81 (99.9)80,626 (99.9)Key Population79,645 (99.9)81 (99.9)80,626 (99.9)Key Population79,645 (99.9)81 (9.9.9)80,626 (99.9)IMCI2867 (3.6)14 (1.4)2881 (3.6)IPD4359 (5.5)149 (15.2)4508 (5.6)IPD71,692 (90.0)813 (82.8)72,505 (89.9)Other783 (1.0)6 (0.6)789 (1.0)Text type, n (%)158 (16.1)8517 (10.6)Repeat Test in < =12 months	40–44	7297 (9.2)	111 (11.3)	7408 (9.2)	50+15,335 (19.2)192 (19.6)15,527 (19.2)Married Nonogamous49,456 (62.1)560 (57.0)50,016 (62.0)Married Polygamous228 (0.3)6 (0.6)234 (0.3)Divorced1942 (2.4)93 (9.5)2035 (2.5)Separated918 (1.2)11 (1.1)929 (1.2)Single27,157 (34.1)312 (31.8)27,469 (34.0)Female27,487 (34.5)318 (32.4)27,805 (34.5)Female27,487 (34.5)318 (32.4)25,878 (65.5)Population Type, n (%)318 (32.4)25,878 (65.5)Key Population79,645 (99.9)981 (99.9)80,626 (99.9)Key Population79,645 (99.9)981 (99.9)80,626 (99.9)Key Population79,645 (99.9)981 (99.0)80,626 (99.9)Formar Testing, n (%)14 (1.4)2881 (3.6)IPD4359 (5.5)149 (15.2)4508 (5.6)OPD71,692 (90.0)813 (82.8)72,505 (89.9)Other78,31 (10.6)8359 (10.5)158 (16.1)8517 (10.6)Repeat Test in < 12 months	45–49	5309 (6.7)	80 (8.1)	5389 (6.7)	Married Monogamous 49,456 (62.1) 560 (57.0) 50,016 (62.0) Married Polygamous 228 (0.3) 6 (0.6) 234 (0.3) Divorced 1942 (2.4) 93 (9.5) 2035 (2.5) Separated 918 (1.2) 11 (1.1) 929 (1.2) Single 27,457 (34.1) 312 (31.8) 27,469 (34.0) Sex, n (%) 318 (32.4) 27,805 (34.5) Female 27,487 (34.5) 318 (32.4) 27,805 (34.5) Female 52,214 (65.5) 664 (67.6) 52,878 (65.5) Pulation Type, n (%) 10.1) 57,010 Egeneral Population 50,01 10.1) 57,010 Eyephytein Testing, n (%) 14 (1.4) 2881 (3.6) IPD 4359 (5.5) 149 (15.2) 4508 (5.6) OPD 71,692 (90.0) 813 (82.8) 72,505 (89.9) Other 783 (1.0) 6 (0.6) 789 (1.0) Eyepat Test in <=12 months	50+	15,335 (19.2)	192 (19.6)	15,527 (19.2)	Married Monogamous49,456 (62.1)560 (57.0)50,016 (62.0)Married Polygamous228 (0.3)6 (0.6)234 (0.3)Divorced1942 (2.4)93 (9.5)2035 (2.5)Separated918 (1.2)11 (1.1)929 (1.2)Single27,467 (34.1)312 (31.8)27,469 (34.0)Sex_r n(%)	Marital Status, n (%)				Married Polygamous228 (0.3)6 (0.6)234 (0.3)Divorced1942 (2.4)93 (9.5)2035 (2.5)Separated918 (1.2)11 (1.1)929 (1.2)Single27,157 (34.1)312 (31.8)27,469 (34.0)Sex, n (%) </td <td>Married Monogamous</td> <td>49,456 (62.1)</td> <td>560 (57.0)</td> <td>50,016 (62.0)</td>	Married Monogamous	49,456 (62.1)	560 (57.0)	50,016 (62.0)	Divorced1942 (2.4)93 (9.5)2035 (2.5)Separated918 (1.2)11 (1.1)929 (1.2)Single27,157 (34.1)312 (31.8)27,469 (34.0)Sex, n (%) </td <td>Married Polygamous</td> <td>228 (0.3)</td> <td>6 (0.6)</td> <td>234 (0.3)</td>	Married Polygamous	228 (0.3)	6 (0.6)	234 (0.3)	Separated single918 (1.2)11 (1.1)929 (1.2)Single27,157 (34.1)312 (31.8)27,469 (34.0)Sex.n (%) </td <td>Divorced</td> <td>1942 (2.4)</td> <td>93 (9.5)</td> <td>2035 (2.5)</td>	Divorced	1942 (2.4)	93 (9.5)	2035 (2.5)	Single 27,157 (34.1) 312 (31.8) 27,469 (34.0) Sex, n (%) 7,487 (34.5) 318 (32.4) 27,805 (34.5) Female 27,487 (34.5) 318 (32.4) 27,805 (34.5) Female 52,214 (65.5) 664 (67.6) 52,878 (65.5) Population Type, n (%) 80,626 (99.9) Key Population 79,645 (99.9) 981 (99.9) 80,626 (99.9) Key Population 56 (0.1) 1 (0.1) 57 (0.1) Department Testing, n (%) 8881 (3.6) IPD 4359 (5.5) 149 (15.2) 4508 (5.6) OPD 71,692 (90.0) 813 (82.8) 72,505 (89.9) Other 783 (1.0) 6 (0.6) 789 (1.0) Test type, n (%) 817 (10.6) Repeat Test in <= 12 months	Separated	918 (1.2)	11 (1.1)	929 (1.2)	Sex, n (%) Male 27,487 (34.5) 318 (32.4) 27,805 (34.5) Male 52,214 (65.5) 664 (67.6) 52,878 (65.5) Population Type, n (%) 80,626 (99.9) Key Population 79,645 (99.9) 981 (99.9) 80,626 (99.9) Key Population 79,645 (99.9) 981 (99.9) 80,626 (99.9) Key Population 56 (0.1) 1 (0.1) 57 (0.1) Department Testing, n (%) 14 (1.4) 2881 (3.6) INCI 2867 (3.6) 149 (15.2) 4508 (5.6) OPD 71,692 (90.0) 813 (82.8) 72,505 (89.9) Other 783 (1.0) 6 (0.6) 789 (1.0) Test type, n (%) 822 (49.1) 46,947 (58.2) Repeat Test in < = 12 months	Single	27,157 (34.1)	312 (31.8)	27,469 (34.0)	Male 27,487 (34.5) 318 (32.4) 27,805 (34.5) Female 52,214 (65.5) 664 (67.6) 52,878 (65.5) Population Type, n (%) 80,626 (99.9) Reneral Population 79,645 (99.9) 981 (99.9) 80,626 (99.9) Key Population 79,645 (99.9) 981 (99.9) 80,626 (99.9) Log Population 70,645 (99.9) 10.10 57 (0.1) Department Testing, n (%) 1 10.10 2881 (3.6) IPD 359 (5.5) 149 (15.2) 4508 (5.6) OPD 71,692 (90.0) 813 (82.8) 72,505 (89.9) Other 783 (1.0) 6 (0.6) 789 (1.0) Repeat Test in < 12 months	Sex, n (%)				Female 52,214 (65.5) 664 (67.6) 52,878 (65.5) Population Type, n (%) 981 (99.9) 80,626 (99.9) Key Population 79,645 (99.9) 981 (99.0) 80,626 (99.9) Key Population 56 (0.1) 1 (0.1) 57 (0.1) Popurtment Testing, n (%) 14 (1.4) 2881 (3.6) IMCI 2867 (3.6) 14 (1.4) 2881 (3.6) IPD 4359 (5.5) 149 (15.2) 4508 (5.6) OPD 71,692 (90.0) 813 (82.8) 72,505 (89.9) Other 783 (1.0) 6 (0.6) 789 (1.0) Fepeat Test in < = 12 months	Male	27,487 (34.5)	318 (32.4)	27,805 (34.5)	Population Type, n (%) 981 (99.9) 80,626 (99.9) General Population 56 (0.1) 1 (0.1) 57 (0.1) Lepartment Testing, n (%) 14 (1.4) 2881 (3.6) IMCI 2867 (3.6) 149 (15.2) 4508 (5.6) IPD 4359 (5.5) 149 (15.2) 4508 (5.6) OPD 71,692 (90.0) 813 (82.8) 72,505 (89.9) Other 783 (1.0) 6 (0.6) 789 (1.0) Fepeat Test in < = 12 months	Female	52,214 (65.5)	664 (67.6)	52,878 (65.5)	General Population 79,645 (99.9) 981 (99.9) 80,626 (99.9) Key Population 56 (0.1) 1 (0.1) 57 (0.1) Department Testing, n (%) 14 (1.4) 2881 (3.6) IMCI 2867 (3.6) 14 (1.4) 2858 (5.6) IPD 4359 (5.5) 149 (15.2) 4508 (5.6) OPD 71,692 (90.0) 813 (82.8) 72,505 (89.9) Other 783 (1.0) 6 (0.6) 789 (1.0) Fepeat Test in < = 12 months	Population Type, n (%)				Key Population 56 (0.1) 1 (0.1) 57 (0.1) IPD 2867 (3.6) 14 (1.4) 2881 (3.6) IPD 4359 (5.5) 149 (15.2) 4508 (5.6) OPD 71,692 (90.0) 813 (82.8) 72,505 (89.9) Other 783 (1.0) 6 (0.6) 789 (1.0) Fepeat Test in < 12 months	General Population	79,645 (99.9)	981 (99.9)	80,626 (99.9)	Pertment Testing, n (%) 2867 (3.6) 14 (1.4) 2881 (3.6) IPD 4359 (5.5) 149 (15.2) 4508 (5.6) OPD 71,692 (90.0) 813 (82.8) 72,505 (89.9) Other 783 (1.0) 6 (0.6) 789 (1.0) Expert Test in < 12 months	Key Population	56 (0.1)	1 (0.1)	57 (0.1)	IMCI 2867 (3.6) 14 (1.4) 2881 (3.6) IPD 4359 (5.5) 149 (15.2) 4508 (5.6) OPD 71,692 (90.0) 813 (82.8) 72,505 (89.9) Other 783 (1.0) 6 (0.6) 789 (1.0) Test type, n (%) 4529 (53.3) 482 (49.1) 46,947 (58.2) Repeat Test in < = 12 months	Department Testing, n (%)				IPD 4359 (5.5) 149 (15.2) 4508 (5.6) OPD 71,692 (90.0) 813 (82.8) 72,505 (89.9) Other 783 (1.0) 6 (0.6) 789 (1.0) Test type, n (%) 822 (49.1) 46,947 (58.2) Repeat Test in <= 12 months	IMCI	2867 (3.6)	14 (1.4)	2881 (3.6)	OPD 71,692 (90.0) 813 (82.8) 72,505 (89.9) Other 783 (1.0) 6 (0.6) 789 (1.0) Test type, n (%) 46,465 (58.3) 482 (49.1) 46,947 (58.2) Repeat Test in < = 12 months	IPD	4359 (5.5)	149 (15.2)	4508 (5.6)	Other 783 (1.0) 6 (0.6) 789 (1.0) Test type, n (%) Repeat Test in < = 12 months	OPD	71,692 (90.0)	813 (82.8)	72,505 (89.9)	Test type, n (%) 48,465 (58.3) 482 (49.1) 46,947 (58.2) Repeat Test in < 12 months	Other	783 (1.0)	6 (0.6)	789 (1.0)	Repeat Test in < = 12 months 46,465 (58.3) 482 (49.1) 46,947 (58.2) Repeat Test in > 12 months 8359 (10.5) 158 (16.1) 8517 (10.6) Never Tested 24,877 (31.2) 342 (34.8) 25,219 (31.3) GBV. n (%) 57,10,6) GBV- None detected 79,436 (99.7) 979 (99.7) 80,415 (99.7) GBV- Physical/Sexual violence 265 (0.3) 3 (0.3) 268 (0.3) TB, n (%) 909 (92.6) 80,076 (99.2) No signs 79,167 (99.3) 909 (92.6) 80,076 (99.2) Not done 15 (0.0) 0 (0.0) 15 (0.0) TB Treatment 159 (0.2) 6 (0.6) 165 (0.2) Presumed TB 360 (0.5) 67 (6.8) 427 (5.5)	Test type, n (%)				Repeat Test in > 12 months 8359 (10.5) 158 (16.1) 8517 (10.6) Never Tested 24,877 (31.2) 342 (34.8) 25,219 (31.3) GBV, n (%) 560 (30.3) 60.9 (30.3) 60.9 (30.3) GBV- None detected 79,436 (99.7) 979 (99.7) 80,415 (99.7) GBV- Physical/Sexual violence 265 (0.3) 3 (0.3) 268 (0.3) TB, n (%) 50,01 909 (92.6) 80,076 (99.2) Nos igns 79,167 (99.3) 909 (92.6) 80,076 (99.2) Not done 15 (0.0) 0 (0.0) 15 (0.0) TB Treatment 159 (0.2) 6 (0.6) 165 (0.2) Presumed TB 360 (0.5) 67 (6.8) 427 (5.5)	Repeat Test in < = 12 months	46,465 (58.3)	482 (49.1)	46,947 (58.2)	Never Tested 24,877 (31.2) 342 (34.8) 25,219 (31.3) GBV- None detected 79,436 (99.7) 979 (99.7) 80,415 (99.7) GBV- Physical/Sexual violence 265 (0.3) 3 (0.3) 268 (0.3) TB, n (%) V V 80,716 (99.2) 80,076 (99.2) No signs 79,167 (99.3) 909 (92.6) 80,076 (99.2) Not done 15 (0.0) 0 (0.0) 15 (0.0) TB Treatment 159 (0.2) 6 (0.6) 165 (0.2) Presumed TB 360 (0.5) 67 (6.8) 427 (0.5)	Repeat Test in > 12 months	8359 (10.5)	158 (16.1)	8517 (10.6)	GBV, n (%) GBV- None detected 79,436 (99.7) 979 (99.7) 80,415 (99.7) GBV- Physical/Sexual violence 265 (0.3) 3 (0.3) 268 (0.3) TB, n (%) 79,167 (99.3) 909 (92.6) 80,076 (99.2) Nos igns 79,167 (99.3) 909 (92.6) 80,076 (99.2) Not done 15 (0.0) 0 (0.0) 15 (0.0) TB Treatment 159 (0.2) 6 (0.6) 165 (0.2) Presumed TB 360 (0.5) 67 (6.8) 427 (0.5)	Never Tested	24,877 (31.2)	342 (34.8)	25,219 (31.3)	GBV- None detected 79,436 (99.7) 979 (99.7) 80,415 (99.7) GBV- Physical/Sexual violence 265 (0.3) 3 (0.3) 268 (0.3) TB, n (%) 79,167 (99.3) 909 (92.6) 80,076 (99.2) Not done 15 (0.0) 0 (0.0) 15 (0.0) TB Treatment 159 (0.2) 6 (0.6) 165 (0.2) Presumed TB 360 (0.5) 67 (6.8) 427 (0.5)	GBV, n (%)				GBV- Physical/Sexual violence 265 (0.3) 3 (0.3) 268 (0.3) TB, n (%) No signs 79,167 (99.3) 909 (92.6) 80,076 (99.2) Not done 15 (0.0) 0 (0.0) 15 (0.0) TB Treatment 159 (0.2) 6 (0.6) 165 (0.2) Presumed TB 360 (0.5) 67 (6.8) 427 (0.5)	GBV- None detected	79,436 (99.7)	979 (99.7)	80,415 (99.7)	TB, n (%) No signs 79,167 (99.3) 909 (92.6) 80,076 (99.2) Not done 15 (0.0) 0 (0.0) 15 (0.0) TB Treatment 159 (0.2) 6 (0.6) 165 (0.2) Presumed TB 360 (0.5) 67 (6.8) 427 (0.5) PrEP Eligibility, n (%) 500 (0.5) 500 (0.5) 500 (0.5)	GBV- Physical/Sexual violence	265 (0.3)	3 (0.3)	268 (0.3)	No signs 79,167 (99.3) 909 (92.6) 80,076 (99.2) Not done 15 (0.0) 0 (0.0) 15 (0.0) TB Treatment 159 (0.2) 6 (0.6) 165 (0.2) Presumed TB 360 (0.5) 67 (6.8) 427 (0.5) PrEP Eligibility, n (%) 5 5 5	TB, n (%)				Not done 15 (0.0) 0 (0.0) 15 (0.0) TB Treatment 159 (0.2) 6 (0.6) 165 (0.2) Presumed TB 360 (0.5) 67 (6.8) 427 (0.5) PrEP Eligibility, n (%) 5 5 5	No signs	79,167 (99.3)	909 (92.6)	80,076 (99.2)	TB Treatment 159 (0.2) 6 (0.6) 165 (0.2) Presumed TB 360 (0.5) 67 (6.8) 427 (0.5) PrEP Eligibility, n (%) 7 7 7	Not done	15 (0.0)	0 (0.0)	15 (0.0)	Presumed TB 360 (0.5) 67 (6.8) 427 (0.5) PrEP Eligibility, n (%) 67 (6.8)	TB Treatment	159 (0.2)	6 (0.6)	165 (0.2)	PrEP Eligibility, n (%)	Presumed TB	360 (0.5)	67 (6.8)	427 (0.5)		PrEP Eligibility, n (%)				Not Eligible 79,512 (99.8) 977 (99.5) 80,489 (99.8)	Not Eligible	79,512 (99.8)	977 (99.5)	80,489 (99.8)	Eligible 189 (0.2) 5 (0.5) 194 (0.2)	Eligible	189 (0.2)	5 (0.5)	194 (0.2)
40–44	7297 (9.2)	111 (11.3)	7408 (9.2)																																																																																																																																																																											
50+15,335 (19.2)192 (19.6)15,527 (19.2)Married Nonogamous49,456 (62.1)560 (57.0)50,016 (62.0)Married Polygamous228 (0.3)6 (0.6)234 (0.3)Divorced1942 (2.4)93 (9.5)2035 (2.5)Separated918 (1.2)11 (1.1)929 (1.2)Single27,157 (34.1)312 (31.8)27,469 (34.0)Female27,487 (34.5)318 (32.4)27,805 (34.5)Female27,487 (34.5)318 (32.4)25,878 (65.5)Population Type, n (%)318 (32.4)25,878 (65.5)Key Population79,645 (99.9)981 (99.9)80,626 (99.9)Key Population79,645 (99.9)981 (99.9)80,626 (99.9)Key Population79,645 (99.9)981 (99.0)80,626 (99.9)Formar Testing, n (%)14 (1.4)2881 (3.6)IPD4359 (5.5)149 (15.2)4508 (5.6)OPD71,692 (90.0)813 (82.8)72,505 (89.9)Other78,31 (10.6)8359 (10.5)158 (16.1)8517 (10.6)Repeat Test in < 12 months	45–49	5309 (6.7)	80 (8.1)	5389 (6.7)																																																																																																																																																																										
Married Monogamous 49,456 (62.1) 560 (57.0) 50,016 (62.0) Married Polygamous 228 (0.3) 6 (0.6) 234 (0.3) Divorced 1942 (2.4) 93 (9.5) 2035 (2.5) Separated 918 (1.2) 11 (1.1) 929 (1.2) Single 27,457 (34.1) 312 (31.8) 27,469 (34.0) Sex, n (%) 318 (32.4) 27,805 (34.5) Female 27,487 (34.5) 318 (32.4) 27,805 (34.5) Female 52,214 (65.5) 664 (67.6) 52,878 (65.5) Pulation Type, n (%) 10.1) 57,010 Egeneral Population 50,01 10.1) 57,010 Eyephytein Testing, n (%) 14 (1.4) 2881 (3.6) IPD 4359 (5.5) 149 (15.2) 4508 (5.6) OPD 71,692 (90.0) 813 (82.8) 72,505 (89.9) Other 783 (1.0) 6 (0.6) 789 (1.0) Eyepat Test in <=12 months	50+	15,335 (19.2)	192 (19.6)	15,527 (19.2)																																																																																																																																																																										
Married Monogamous49,456 (62.1)560 (57.0)50,016 (62.0)Married Polygamous228 (0.3)6 (0.6)234 (0.3)Divorced1942 (2.4)93 (9.5)2035 (2.5)Separated918 (1.2)11 (1.1)929 (1.2)Single27,467 (34.1)312 (31.8)27,469 (34.0)Sex_r n(%)	Marital Status, n (%)																																																																																																																																																																													
Married Polygamous228 (0.3)6 (0.6)234 (0.3)Divorced1942 (2.4)93 (9.5)2035 (2.5)Separated918 (1.2)11 (1.1)929 (1.2)Single27,157 (34.1)312 (31.8)27,469 (34.0)Sex, n (%) </td <td>Married Monogamous</td> <td>49,456 (62.1)</td> <td>560 (57.0)</td> <td>50,016 (62.0)</td>	Married Monogamous	49,456 (62.1)	560 (57.0)	50,016 (62.0)																																																																																																																																																																										
Divorced1942 (2.4)93 (9.5)2035 (2.5)Separated918 (1.2)11 (1.1)929 (1.2)Single27,157 (34.1)312 (31.8)27,469 (34.0)Sex, n (%) </td <td>Married Polygamous</td> <td>228 (0.3)</td> <td>6 (0.6)</td> <td>234 (0.3)</td>	Married Polygamous	228 (0.3)	6 (0.6)	234 (0.3)																																																																																																																																																																										
Separated single918 (1.2)11 (1.1)929 (1.2)Single27,157 (34.1)312 (31.8)27,469 (34.0)Sex.n (%) </td <td>Divorced</td> <td>1942 (2.4)</td> <td>93 (9.5)</td> <td>2035 (2.5)</td>	Divorced	1942 (2.4)	93 (9.5)	2035 (2.5)																																																																																																																																																																										
Single 27,157 (34.1) 312 (31.8) 27,469 (34.0) Sex, n (%) 7,487 (34.5) 318 (32.4) 27,805 (34.5) Female 27,487 (34.5) 318 (32.4) 27,805 (34.5) Female 52,214 (65.5) 664 (67.6) 52,878 (65.5) Population Type, n (%) 80,626 (99.9) Key Population 79,645 (99.9) 981 (99.9) 80,626 (99.9) Key Population 56 (0.1) 1 (0.1) 57 (0.1) Department Testing, n (%) 8881 (3.6) IPD 4359 (5.5) 149 (15.2) 4508 (5.6) OPD 71,692 (90.0) 813 (82.8) 72,505 (89.9) Other 783 (1.0) 6 (0.6) 789 (1.0) Test type, n (%) 817 (10.6) Repeat Test in <= 12 months	Separated	918 (1.2)	11 (1.1)	929 (1.2)																																																																																																																																																																										
Sex, n (%) Male 27,487 (34.5) 318 (32.4) 27,805 (34.5) Male 52,214 (65.5) 664 (67.6) 52,878 (65.5) Population Type, n (%) 80,626 (99.9) Key Population 79,645 (99.9) 981 (99.9) 80,626 (99.9) Key Population 79,645 (99.9) 981 (99.9) 80,626 (99.9) Key Population 56 (0.1) 1 (0.1) 57 (0.1) Department Testing, n (%) 14 (1.4) 2881 (3.6) INCI 2867 (3.6) 149 (15.2) 4508 (5.6) OPD 71,692 (90.0) 813 (82.8) 72,505 (89.9) Other 783 (1.0) 6 (0.6) 789 (1.0) Test type, n (%) 822 (49.1) 46,947 (58.2) Repeat Test in < = 12 months	Single	27,157 (34.1)	312 (31.8)	27,469 (34.0)																																																																																																																																																																										
Male 27,487 (34.5) 318 (32.4) 27,805 (34.5) Female 52,214 (65.5) 664 (67.6) 52,878 (65.5) Population Type, n (%) 80,626 (99.9) Reneral Population 79,645 (99.9) 981 (99.9) 80,626 (99.9) Key Population 79,645 (99.9) 981 (99.9) 80,626 (99.9) Log Population 70,645 (99.9) 10.10 57 (0.1) Department Testing, n (%) 1 10.10 2881 (3.6) IPD 359 (5.5) 149 (15.2) 4508 (5.6) OPD 71,692 (90.0) 813 (82.8) 72,505 (89.9) Other 783 (1.0) 6 (0.6) 789 (1.0) Repeat Test in < 12 months	Sex, n (%)																																																																																																																																																																													
Female 52,214 (65.5) 664 (67.6) 52,878 (65.5) Population Type, n (%) 981 (99.9) 80,626 (99.9) Key Population 79,645 (99.9) 981 (99.0) 80,626 (99.9) Key Population 56 (0.1) 1 (0.1) 57 (0.1) Popurtment Testing, n (%) 14 (1.4) 2881 (3.6) IMCI 2867 (3.6) 14 (1.4) 2881 (3.6) IPD 4359 (5.5) 149 (15.2) 4508 (5.6) OPD 71,692 (90.0) 813 (82.8) 72,505 (89.9) Other 783 (1.0) 6 (0.6) 789 (1.0) Fepeat Test in < = 12 months	Male	27,487 (34.5)	318 (32.4)	27,805 (34.5)																																																																																																																																																																										
Population Type, n (%) 981 (99.9) 80,626 (99.9) General Population 56 (0.1) 1 (0.1) 57 (0.1) Lepartment Testing, n (%) 14 (1.4) 2881 (3.6) IMCI 2867 (3.6) 149 (15.2) 4508 (5.6) IPD 4359 (5.5) 149 (15.2) 4508 (5.6) OPD 71,692 (90.0) 813 (82.8) 72,505 (89.9) Other 783 (1.0) 6 (0.6) 789 (1.0) Fepeat Test in < = 12 months	Female	52,214 (65.5)	664 (67.6)	52,878 (65.5)																																																																																																																																																																										
General Population 79,645 (99.9) 981 (99.9) 80,626 (99.9) Key Population 56 (0.1) 1 (0.1) 57 (0.1) Department Testing, n (%) 14 (1.4) 2881 (3.6) IMCI 2867 (3.6) 14 (1.4) 2858 (5.6) IPD 4359 (5.5) 149 (15.2) 4508 (5.6) OPD 71,692 (90.0) 813 (82.8) 72,505 (89.9) Other 783 (1.0) 6 (0.6) 789 (1.0) Fepeat Test in < = 12 months	Population Type, n (%)																																																																																																																																																																													
Key Population 56 (0.1) 1 (0.1) 57 (0.1) IPD 2867 (3.6) 14 (1.4) 2881 (3.6) IPD 4359 (5.5) 149 (15.2) 4508 (5.6) OPD 71,692 (90.0) 813 (82.8) 72,505 (89.9) Other 783 (1.0) 6 (0.6) 789 (1.0) Fepeat Test in < 12 months	General Population	79,645 (99.9)	981 (99.9)	80,626 (99.9)																																																																																																																																																																										
Pertment Testing, n (%) 2867 (3.6) 14 (1.4) 2881 (3.6) IPD 4359 (5.5) 149 (15.2) 4508 (5.6) OPD 71,692 (90.0) 813 (82.8) 72,505 (89.9) Other 783 (1.0) 6 (0.6) 789 (1.0) Expert Test in < 12 months	Key Population	56 (0.1)	1 (0.1)	57 (0.1)																																																																																																																																																																										
IMCI 2867 (3.6) 14 (1.4) 2881 (3.6) IPD 4359 (5.5) 149 (15.2) 4508 (5.6) OPD 71,692 (90.0) 813 (82.8) 72,505 (89.9) Other 783 (1.0) 6 (0.6) 789 (1.0) Test type, n (%) 4529 (53.3) 482 (49.1) 46,947 (58.2) Repeat Test in < = 12 months	Department Testing, n (%)																																																																																																																																																																													
IPD 4359 (5.5) 149 (15.2) 4508 (5.6) OPD 71,692 (90.0) 813 (82.8) 72,505 (89.9) Other 783 (1.0) 6 (0.6) 789 (1.0) Test type, n (%) 822 (49.1) 46,947 (58.2) Repeat Test in <= 12 months	IMCI	2867 (3.6)	14 (1.4)	2881 (3.6)																																																																																																																																																																										
OPD 71,692 (90.0) 813 (82.8) 72,505 (89.9) Other 783 (1.0) 6 (0.6) 789 (1.0) Test type, n (%) 46,465 (58.3) 482 (49.1) 46,947 (58.2) Repeat Test in < = 12 months	IPD	4359 (5.5)	149 (15.2)	4508 (5.6)																																																																																																																																																																										
Other 783 (1.0) 6 (0.6) 789 (1.0) Test type, n (%) Repeat Test in < = 12 months	OPD	71,692 (90.0)	813 (82.8)	72,505 (89.9)																																																																																																																																																																										
Test type, n (%) 48,465 (58.3) 482 (49.1) 46,947 (58.2) Repeat Test in < 12 months	Other	783 (1.0)	6 (0.6)	789 (1.0)																																																																																																																																																																										
Repeat Test in < = 12 months 46,465 (58.3) 482 (49.1) 46,947 (58.2) Repeat Test in > 12 months 8359 (10.5) 158 (16.1) 8517 (10.6) Never Tested 24,877 (31.2) 342 (34.8) 25,219 (31.3) GBV. n (%) 57,10,6) GBV- None detected 79,436 (99.7) 979 (99.7) 80,415 (99.7) GBV- Physical/Sexual violence 265 (0.3) 3 (0.3) 268 (0.3) TB, n (%) 909 (92.6) 80,076 (99.2) No signs 79,167 (99.3) 909 (92.6) 80,076 (99.2) Not done 15 (0.0) 0 (0.0) 15 (0.0) TB Treatment 159 (0.2) 6 (0.6) 165 (0.2) Presumed TB 360 (0.5) 67 (6.8) 427 (5.5)	Test type, n (%)																																																																																																																																																																													
Repeat Test in > 12 months 8359 (10.5) 158 (16.1) 8517 (10.6) Never Tested 24,877 (31.2) 342 (34.8) 25,219 (31.3) GBV, n (%) 560 (30.3) 60.9 (30.3) 60.9 (30.3) GBV- None detected 79,436 (99.7) 979 (99.7) 80,415 (99.7) GBV- Physical/Sexual violence 265 (0.3) 3 (0.3) 268 (0.3) TB, n (%) 50,01 909 (92.6) 80,076 (99.2) Nos igns 79,167 (99.3) 909 (92.6) 80,076 (99.2) Not done 15 (0.0) 0 (0.0) 15 (0.0) TB Treatment 159 (0.2) 6 (0.6) 165 (0.2) Presumed TB 360 (0.5) 67 (6.8) 427 (5.5)	Repeat Test in < = 12 months	46,465 (58.3)	482 (49.1)	46,947 (58.2)																																																																																																																																																																										
Never Tested 24,877 (31.2) 342 (34.8) 25,219 (31.3) GBV- None detected 79,436 (99.7) 979 (99.7) 80,415 (99.7) GBV- Physical/Sexual violence 265 (0.3) 3 (0.3) 268 (0.3) TB, n (%) V V 80,716 (99.2) 80,076 (99.2) No signs 79,167 (99.3) 909 (92.6) 80,076 (99.2) Not done 15 (0.0) 0 (0.0) 15 (0.0) TB Treatment 159 (0.2) 6 (0.6) 165 (0.2) Presumed TB 360 (0.5) 67 (6.8) 427 (0.5)	Repeat Test in > 12 months	8359 (10.5)	158 (16.1)	8517 (10.6)																																																																																																																																																																										
GBV, n (%) GBV- None detected 79,436 (99.7) 979 (99.7) 80,415 (99.7) GBV- Physical/Sexual violence 265 (0.3) 3 (0.3) 268 (0.3) TB, n (%) 79,167 (99.3) 909 (92.6) 80,076 (99.2) Nos igns 79,167 (99.3) 909 (92.6) 80,076 (99.2) Not done 15 (0.0) 0 (0.0) 15 (0.0) TB Treatment 159 (0.2) 6 (0.6) 165 (0.2) Presumed TB 360 (0.5) 67 (6.8) 427 (0.5)	Never Tested	24,877 (31.2)	342 (34.8)	25,219 (31.3)																																																																																																																																																																										
GBV- None detected 79,436 (99.7) 979 (99.7) 80,415 (99.7) GBV- Physical/Sexual violence 265 (0.3) 3 (0.3) 268 (0.3) TB, n (%) 79,167 (99.3) 909 (92.6) 80,076 (99.2) Not done 15 (0.0) 0 (0.0) 15 (0.0) TB Treatment 159 (0.2) 6 (0.6) 165 (0.2) Presumed TB 360 (0.5) 67 (6.8) 427 (0.5)	GBV, n (%)																																																																																																																																																																													
GBV- Physical/Sexual violence 265 (0.3) 3 (0.3) 268 (0.3) TB, n (%) No signs 79,167 (99.3) 909 (92.6) 80,076 (99.2) Not done 15 (0.0) 0 (0.0) 15 (0.0) TB Treatment 159 (0.2) 6 (0.6) 165 (0.2) Presumed TB 360 (0.5) 67 (6.8) 427 (0.5)	GBV- None detected	79,436 (99.7)	979 (99.7)	80,415 (99.7)																																																																																																																																																																										
TB, n (%) No signs 79,167 (99.3) 909 (92.6) 80,076 (99.2) Not done 15 (0.0) 0 (0.0) 15 (0.0) TB Treatment 159 (0.2) 6 (0.6) 165 (0.2) Presumed TB 360 (0.5) 67 (6.8) 427 (0.5) PrEP Eligibility, n (%) 500 (0.5) 500 (0.5) 500 (0.5)	GBV- Physical/Sexual violence	265 (0.3)	3 (0.3)	268 (0.3)																																																																																																																																																																										
No signs 79,167 (99.3) 909 (92.6) 80,076 (99.2) Not done 15 (0.0) 0 (0.0) 15 (0.0) TB Treatment 159 (0.2) 6 (0.6) 165 (0.2) Presumed TB 360 (0.5) 67 (6.8) 427 (0.5) PrEP Eligibility, n (%) 5 5 5	TB, n (%)																																																																																																																																																																													
Not done 15 (0.0) 0 (0.0) 15 (0.0) TB Treatment 159 (0.2) 6 (0.6) 165 (0.2) Presumed TB 360 (0.5) 67 (6.8) 427 (0.5) PrEP Eligibility, n (%) 5 5 5	No signs	79,167 (99.3)	909 (92.6)	80,076 (99.2)																																																																																																																																																																										
TB Treatment 159 (0.2) 6 (0.6) 165 (0.2) Presumed TB 360 (0.5) 67 (6.8) 427 (0.5) PrEP Eligibility, n (%) 7 7 7	Not done	15 (0.0)	0 (0.0)	15 (0.0)																																																																																																																																																																										
Presumed TB 360 (0.5) 67 (6.8) 427 (0.5) PrEP Eligibility, n (%) 67 (6.8)	TB Treatment	159 (0.2)	6 (0.6)	165 (0.2)																																																																																																																																																																										
PrEP Eligibility, n (%)	Presumed TB	360 (0.5)	67 (6.8)	427 (0.5)																																																																																																																																																																										
	PrEP Eligibility, n (%)																																																																																																																																																																													
Not Eligible 79,512 (99.8) 977 (99.5) 80,489 (99.8)	Not Eligible	79,512 (99.8)	977 (99.5)	80,489 (99.8)																																																																																																																																																																										
Eligible 189 (0.2) 5 (0.5) 194 (0.2)	Eligible	189 (0.2)	5 (0.5)	194 (0.2)																																																																																																																																																																										

Sd standard deviation

Results

Socio-demographic characteristics of clients

A total of 80,683 clients had an HIV test done between October 2018 to September 2019 as shown in Table 1. Of these, 52,878 (65.5%) were female, 4,894 (6.1%) were less than 15 years old, and 50,016 (62.0%) were in a married monogamous relationship. More than two-thirds 55,464 (68.7%) had previously tested for HIV.

HIV testing outcome

The overall HIV positivity rate among the clients tested was 1.2% (982/80,683). HIV positivity rate was 1.4% (n = 342) among the 25,219 first-time testers, 1.0% (n = 482) among those who had previously tested ('repeat testers') for HIV within 12 months, and 1.9% (n = 158) among the repeat testers in over 12 months. The highest positivity rates were among ages 25–34 [286 (1.3%)], 35–44 [269 (1.6%)], and 45–54 [164 (1.6%)] as shown in Table 1.

Client characteristics associated with a positive test Univariable analysis

On univariable analysis, adults aged 25 to 29, 30 to 34, 35 to 39, and 40 to 49 years compared to children less than 15 years were associated with significantly higher odds of having a positive HIV test result (Table 2). Divorced and married polygamous clients compared to married monogamous ones had higher odds of having a positive HIV result, OR 2.41, 95% CI (1.48–3.94) and OR 3.98, 95% (2.12–7.29) respectively. Female clients compared to males also had higher odds of having a positive HIV test result, OR 1.27, 95% CI (1.03–1.57). Clients tested at IMCI, outpatient, or other departments compared to IPD were less likely to have a positive HIV test result [OR 0.14 95% CI (0.12–0.17), OR 0.33 95% CI (0.20–0.55), and OR 0.22 (0.19–0.26) respectively] (Table 2).

Newly tested clients and those having a repeat test after 12 months compared to <12 months had significantly higher odds of having a positive HIV test result (OR 1.33, 95% CI (1.09-1.62) and (OR 1.82, 95% CI (1.32-2.52) respectively as shown in Table 2. The presumptive TB clients compared to clients with no signs of TB had significantly higher odds of having a positive HIV test result, (OR 16.21, 95% CI (8.32-31.57) (Table 2).

Multivariable analysis

On multivariable analysis, being an adult (15 years plus) aged, 20 to 24, 25 to 29, 30 to 34, 35 to 39, 40 to 49, and 50 plus years compared to children less than 15 years was associated with significantly higher odds of having a positive HIV test result, [aOR 1.65 95% CI (1.01–2.69), aOR 2.45 95% CI (1.61–3.74), aOR 3.40 95% CI (1.54–7.51), aOR 3.75 95% CI (1.79–7.83), aOR 3.16 95% CI

(1.56–6.43), aOR 3.06 95% CI (1.64–5.70), and aOR 2.57 (1.27–5.17) respectively] as shown in Table 2. Female clients had significantly higher odds of having a positive HIV test result compared to males (aOR 1.27, 95% CI (1.03–1.57). Divorced clients and married polygamous compared to married monogamous ones also had significantly higher odds of having a positive HIV result [aOR 3.98, 95% CI (2.12–7.29) and aOR 2.41 95% CI (1.48–3.94)] respectively. Those clients tested in IMCI, OPD, or other departments were still less likely to have a positive HIV test result using IPD as a reference, [aOR 0.15 95% CI (0.10–0.24), aOR 0.26 95% CI (0.13–0.54), and aOR 0.26 (0.14–0.46)] respectively as shown in Table 2.

New clients testing for the first time compared to repeat testers in less than 12 months had significantly higher odds of having a positive HIV test result (aOR 1.39, 95% CI (1.27–1.51). Similarly, repeat testers in more than 12 months compared to repeat testers in less than 12 months also had significantly higher odds of having a positive HIV test result (aOR 1.90, 95% CI (1.55–2.32). Presumptive TB clients compared to those with no signs of TB had significantly higher odds of having a positive HIV test result (aOR 16.25, 95% CI (10.63–24.84)), as shown in Table 2.

Key populations (MSM, PWID, FSW) and GBV status did not meet the model probability inclusion criteria and were therefore not included in the final multivariable model.

Discussion

Our study looked at the demographic and clinical characteristics of persons who tested HIV positive in central Kenya. Older clients aged over 20 years and above had significantly higher odds of testing HIV positive compared to those below 15 years. Among all age groups, this study showed that clients aged 35-39 years had the highest odds of testing HIV positive as compared to clients below 15 years. This finding differs from a study carried out in rural Kenya and Uganda which showed that more HIV infections were among persons aged 15–34 years [1, 13] and the KENPHIA 2018 report which showed that prevalence peaked among adults aged 45 to 49 years. The reason for this difference may be explained by the geographical differences in the HIV epidemic between Kenya and Uganda, with Uganda being classified under countries with > 10% adult prevalence as compared to Kenya which is classified under countries with adult prevalence of between 1-5% [5]. Another reason for the differences could be that the KENPHIA assessment covered the entire country whereas this study was only conducted in three counties in central Kenya.

Our study showed that the divorced and married polygamous were more likely to test HIV-positive compared to

Outcome: Positive vs. Negative HIV test result	Univariable Odds Ratio (95% Cl)	P value	Multivariable Odds Ratio (95% Cl) ^a	P value
County				
Murang'a	Reference		Reference	
Nyandarua	1.32 (0.62–2.82)	0.473	1.28 (0.70–2.34)	0.418
Nyeri	0.77 (0.36–1.65)	0.508	0.73 (0.42-1.28)	0.273
Age category (Years)				
<15	Reference		Reference	
15–19	0.89 (0.51–1.55)	0.672	0.99 (0.56–1.75)	0.961
20-24	1.21 (0.77-1.90)	0.406	1.65 (1.01–2.69)	0.044
25–29	1.64 (1.18–2.27)	0.003	2.45 (1.61-3.74)	< 0.001
30–34	2.25 (1.24-4.10)	0.008	3.40 (1.54–7.51)	0.003
35–39	2.60 (1.49–4.52)	0.001	3.75 (1.79–7.83)	< 0.001
40-44	2.24 (1.24–4.06)	0.008	3.16 (1.56–6.43)	0.001
45–49	2.22 (1.29–3.83)	0.004	3.06 (1.64–5.70)	< 0.001
50+	1.84 (1.04–3.27)	0.036	2.57 (1.27–5.17)	0.009
Marital Status				
Married Monogamous	Reference		Reference	
Married Polygamous	2.32 (1.53-3.53)	< 0.001	2.41 (1.48–3.94)	< 0.001
Divorced	4.23 (2.28–7.85)	< 0.001	3.98 (2.17–7.29)	< 0.001
Separated	1.06 (0.63–1.78)	0.831	0.96 (0.54–1.73)	0.900
Single	1 02 (0 74–1 39)	0.928	1 50 (0 92–2 47)	0.106
Sex		0.520		01100
Male	Reference		Reference	
Female	1 10 (0.86–1.41)	0.452	1 27 (1 03–1 57)	0.028
Population Type	1110 (0.00 1111)	0.152	1.27 (1.05 1.57)	0.020
General Population	Reference			
Key Population	1 45 (0 07-31 19)	0.812		
Department Testing		0.012		
IMCI	0 14 (0 12-0 17)	< 0.001	0 15 (0 10-0 24)	< 0.001
IPD	Reference	< 0.001	Reference	< 0.001
	0.33 (0.20-0.55)	< 0.001	0.26 (0.13-0.54)	< 0.001
Other	0.22 (0.19-0.26)	< 0.001	0.26 (0.13-0.51)	< 0.001
	0.22 (0.19-0.20)	< 0.001	0.20 (0.14-0.40)	< 0.001
Popost Tost in < -12 months	Reference		Poforonco	
Repeat Test in ≥ 12 months	1.82 (1.32, 2.52)	< 0.001	1 00 (1 55 2 32)	< 0.001
NoverTested	1.32 (1.00, 1.62)	0.006	$1.30(1.37 \pm 1.51)$	< 0.001
Conder-Based Violence	1.55 (1.02)	0.000	1.59 (1.27 - 1.51)	< 0.001
GBV/- None datacted	Reference			
		0.022		
Tuborculosic	0.92 (0.13-0.07)	0.955		
No signs	Poforonco		Poforonco	
Not dono		_		_
		-		-
	ンビン (U.D.) ビン(U) ビン(U) ビン(U)	0.195	2.77 (0.05 - 11.87)	U.109
	10.21 (8.32-31.57)	< 0.001	10.25 (10.03–24.84)	< 0.001
	Deference		Deference	
NOL EIIGIDIE		0.110		0147
Eligible	2.15 (0.84–5.51)	0.110	1.77 (0.82-3.80)	0.14/

^a Backward stepwise model selection used

the married monogamous. This is consistent with a systematic review done in seven sub-Saharan African countries and three other studies carried out in Kenya [11, 17–21] which reported that the divorced/separated were significantly more likely to be HIV-positive compared to the married. While marital status may not be a prominent indicator in HIV eligibility screening tools, our study suggests its potentially important role in improving yield and should be incorporated in risk assessment for testing in Kenya and similar settings.

Female clients seeking health services were more likely to test HIV-positive as compared to male clients. This corroborates a finding of a study carried out in rural Kenya and Uganda and population-based HIV impact assessments done in Kenya, Uganda, and Tanzania which reported that women comprised of a majority of those likely to test HIV-positive [17]. This further corroborates population-based HIV impact assessments (PHIAs) done in Kenya, Uganda, Tanzania, and Rwanda that indicated that more females were HIV infected than males [1, 21–23]. This could be because of better health-seeking behavior among females than males, coupled with female biological and socio-cultural vulnerabilities, such as a lack of power to bargain for condom use during sex [24]. For this reason, service delivery points visited by female clients could be strengthened by including an HTS provider offering testing services to maximize testing and yield.

Patients tested at IPD were more likely to test HIV positive as compared to those tested at IMCI and other departments. This is consistent with a finding of a study carried out in several sub-Saharan countries which reported that PITC among inpatients had the highest positivity rate compared to other testing departments [25]. This is because clients already admitted in hospitals (if HIV infected) would likely show symptoms of HIV infection and be easy to reach hence the explanation for the high positivity rate compared to other departments. This means that for effective yield in inpatient departments, strategies could be put in place to screen all admitted patients for HTS eligibility and offer 'opt-out' HIV testing to all those eligible while addressing concerns about privacy and stigma in crowded spaces [25]. Patient education on the need to test for those admitted for other illnesses could be encouraged to reduce the chances of opting out of the HIV test.

Clients testing for the first time were more likely to test HIV-positive as compared to repeat testers. This reflects similar findings from two studies done in Kenya which showed that HIV-positive results were more common among first-time testers [18, 26]. This is explained by some factors such as the client's location far from the testing facility, lower age bracket of 18–24, and low education level [27]. Including questions in HIV screening tools that explore why first-time testers do not test when they visit a health facility could help to improve access.

Clients having a repeat test after 12 months were more likely to test HIV-positive compared to those having a repeat test in less than 12 months. This concurs with two studies done in Kenya which showed that HIV-positive test results were most common among first-time testers and late re-testers [24]- 27. With frequent testing, clients receive prevention messages during the testing and counseling session and are likely to follow the prevention measures given. This could be a possible reason why repeat testers after 12 months are likely to test HIV-positive as compared to those who repeat tests in less than 12 months. Programs in Kenya and similar settings should optimize HTS eligibility screening to identify first-time testers and late retesters to be prioritised for HIV testing to improve yield. Stakeholders could also educate clients to increase awareness of the need for HIV testing for those never tested and at risk and among late retesters.

Presumptive TB clients were more likely to test HIV-positive compared to those with no signs of TB. This finding is consistent with studies done in Nairobi, Kenya, and India which showed that persons with symptoms of TB had an HIV prevalence of 61% [28] and a 12% yield respectively among patients with presumptive TB [29]. This is because TB is among the major opportunistic infections in HIV-infected persons [18, 19]. This means that all clients presenting at the health facilities with signs suggestive of TB need to be screened for HTS eligibility with fidelity and tested. This also calls for streamlining patient flows in TB clinics to ensure all patients in such departments are tested for HIV, reducing missed opportunities. Programs in Kenya and similar settings should optimize presumptive TB screening as an important opportunity to increase yield from HIV testing.

GBV status was not significantly associated with HIV positivity in this study. This however contrasts with a study carried out in the South Wollo zone, Ethiopia which reported that partner sexual violence by another perpetrator was strongly associated with HIV infection [30]. There is a need to tailor-make the eligibility screening process for individuals undergoing GBV, who are at ongoing risk for HIV infection in the central region of Kenya.

PrEP eligibility was not significantly associated with HIV positivity in this study. This is central to the WHO recommendation that PrEP be offered to populations at substantial ongoing risk. This calls for further study on PrEP eligibility and HIV positivity in different settings.

Key populations (MSM, FSW, PWID) did not show any significant association with HIV positivity. The limitation in measurement of this particular variable is that this study was carried out in a general population setting with only 57 clients identified as key population, and only one turning out to be HIV-positive; hence, could give a misleading picture because of the low numbers used. This differs from a report by UNAIDS that reported the rate of new adult infections among the key population and their sexual partners was 62%. Key populations are disproportionately affected by HIV and have higher morbidity and mortality rates than the general population [5]. This calls for the development of screening tools that look out for key population individuals seeking hospital services and offer them HIV testing services.

Study limitations

This study had some limitations. First, the use of crosssectional and routine program data that is captured in paper-based registers would not allow us to examine cause and effect. Secondly, transcription errors may have occurred during the process of data abstraction from registers to the electronic system and could lead to study biases. Another limitation was on variables used in the analysis in that some key HIV-positive predictor variables, like lifestyle, and education level, among others, were not evaluated because the study was limited to variables available in the HTS laboratory register. Lastly, the study included a limited number of key populations thereby affecting the generalizability of the results to them.

Conclusion

We found that client characteristics such as age, marital status, HIV test entry point, first-time test, repeat test after 12 months, and TB status are potentially predictive of the outcome of HIV case finding in PITC settings in central Kenya. The factors highlighted as determinants of a positive HIV test in this study can be used to develop a screening tool to target high-risk clients for HTS in similar settings. To the best of our knowledge, no similar study using a large dataset from the three central Kenya counties has been done. The researchers intend to build a prognostic risk model based on the multivariate model that will be trained, tested, calibrated, and validated to have a predictive capability to classify HTS clients as either low, medium, or high risk in low HIV prevalence settings.

Abbreviations

Abbievia	10113
aPNS	Assisted partner notification services
ART	Antiretroviral therapy
CDC	Centers for Disease Control and Prevention
CHS	Centre for Health Solutions - Kenya
CI	Confidence Interval
FSW	Female sex workers
GBV	Gender based violence
IMCI	Integrated management of childhood illnesses
IPD	Inpatient department
MOH	Ministry of Health
KENPHIA	The Kenya Population-based HIV Impact Assessment
MSM	Men who have sex with men
NASCOP	National AIDS and STI Control Program
OPD	Outpatient department
OR	Odds Ratio
PEPFAR	President's Emergency Plan for AIDS Relief
PLHIV	People living with HIV
PMTCT	Prevention of mother-to-child transmission of HIV
PITC	Provider initiated testing and counselling
PrEP	Pre-exposure prophylaxis
PWID	People who inject drugs
SNS	Social network strategies
SSA	Sub-Saharan Africa
STI	Sexually transmitted infections
SQL	Structured Query Language
ТВ	Tuberculosis
UNAIDS	The Joint United Nations Programme on HIV/AIDS
WHO	World Health Organization

Acknowledgements

We acknowledge the support of the county health management teams, and all health care workers for their work in providing HTS ensuring complete documentation, CHS leadership for guidance and direction, the health information systems team for developing the data collection application, and the monitoring and evaluation team for coordinating data collection at health facilities. We also thank all the amazing clients we served without whose data this study would not be possible.

Authors' contributions

All authors (RM, KO, JMU, JMW, and PW) made significant contributions in interpretation of the data and also gave approval for the final paper. RM, JMU, KO, and PW developed the idea and were in charge of study implementation including data collection. KO, RM and PW were involved in data management, analysis, and results writeup. RM, JMU, PW, and KO contributed to drafting and revising the manuscript with guidance and intellectual input from co-authors (JMW). PW and KO have access to the data and take responsibility for the integrity and accuracy of the data. All authors contributed substantially to the interpretation of the data and approved the final manuscript.

Attribution of support

This study was supported by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention (CDC) under the terms of Cooperative Agreement No. GH002024 CHS Tegemeza+.

Disclaimer

The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the official position of the funding agencies.

Funding

This manuscript has been supported by funding from the President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) under the terms of cooperative agreement GH002024. The funding body did not play any role in the study design and collection, analysis, and interpretation of data and in the writing of this manuscript.

Availability of data and materials

The dataset used is a deidentified dataset with individual-level routine HIV testing data and is not currently publically available as it is the property of the Ministry of Health and the Government of Kenya. The dataset can be obtained from the corresponding author based on a reasonable request.

Declarations

Ethics approval and consent to participate

This study was approved by the Kenyatta National Hospital—University of Nairobi Ethics Review Committee. The study was reviewed according to the Centers for Disease Control and Prevention (CDC) human research protection procedures and was determined to be and approved as research, but CDC was not engaged. As this research was retrospective, the Kenyatta National Hospital – University of Nairobi Ethics Review Committee waived the need for consent from study participants. All methods were carried out in accordance with relevant guidelines and regulations.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Author details

¹Centre for Health Solutions, Nairobi, Kenya. ²Division of Global HIV & TB, Center for Global Health, US Centers for Disease Control and Prevention, Nairobi, Kenya.

Received: 17 November 2022 Accepted: 4 August 2023 Published online: 19 September 2023

References

- 1. NASCOP. "KENPHIA 2018 Preliminary Report," 2020.
- 2. PEPFAR. "PEPFAR 2021 Country and Regional Operational Plan (COP / ROP) Guidance for all PEPFAR Countries," USA: WHo; 2020. p. 2020.
- PEPFAR, "PEPFAR DATIM database." [Online]. Available: https://www.datim. org/. [Accessed: 09-Aug-2022].
- 4. UNAIDS. "Understanding Fast-Track Targets. Accelerating action to end the AIDS epidemic by 2030," 2015.
- 5. UNAIDS. Programme on HIV/AIDS: Data 2020. 2020.
- Wekesa P. et al., "Time to HIV testing of sexual contacts identified by HIV-positive index clients in Siaya County, Kenya," PLoS One, vol. 15, no. 9 September, pp. 1–11, 2020.
- 7. PEPFAR. 2020 Annual Report to Congress. 2020.
- 8. M. D. Quigless. Consolidated Guidelines on HIV Testing Services. 2019.
- G. Antelman et al., "Balancing HIV testing efficiency with HIV caseidentification among children and adolescents (2–19 years) using an HIV risk screening approach in Tanzania," PLoS One, vol. 16, no. 5 May, pp. 1–16, 2021.
- 10. NASCOP. The Kenya HIV Testing Services Guidelines. 2015. p. 1–78.
- 11. K. N. B. of Statistics, Kenya population and housing census volume 1: Population by County and sub-County, vol. I, no. November. 2019.
- Wekesa P, McLigeyo A, Owuor K, Mwangi J, Nganga E, Masamaro K. Factors associated with 36-month loss to follow-up and mortality outcomes among HIV-infected adults on antiretroviral therapy in Central Kenya. BMC Public Health. 2020;20(1):1–11.
- Wekesa P, McLigeyo A, Owuor K, Mwangi J, Isavwa L, Katana A. Temporal trends in pre-ART patient characteristics and outcomes before the test and treat era in Central Kenya. BMC Infect Dis. 2021;21(1):1–10.
- McLigeyo A, Wekesa P, Owuor K, Mwangi J, Isavwa L, Mutisya I. Factors Associated with Treatment Outcomes among Children and Adolescents Living with HIV Receiving Antiretroviral Therapy in Central Kenya. AIDS Res Hum Retroviruses. 2022;38(6):480–90.
- Wekesa P, McLigeyo A, Owuor K, Mwangi J, Ngugi E. Survival probability and factors associated with time to loss to follow-up and mortality among patients on antiretroviral treatment in central Kenya. BMC Infect Dis. 2022;22(1):1–10.

- 17. Nyabuti MN, et al. Characteristics of HIV seroconverters in the setting of universal test and treat: Results from the SEARCH trial in rural Uganda and Kenya. PLoS One. 2021;16(2):1–13.
- 18. Tenkorang EY. Marriage, widowhood, divorce and HIV risks among women in sub-Saharan Africa. Int Health. 2014;6(1):46–53.
- Kimanga DO, et al. Prevalence and Incidence of HIV Infection, Trends, and Risk Factors Among Persons Aged 15–64 Years in Kenya. JAIDS J Acquir Immune Defic Syndr. 2014;66(Supplement 1):S13–26.
- Kimani JK, Ettarh R, Ziraba AK, Yatich N. Marital status and risk of HIV infection in slum settlements of Nairobi, Kenya: results from a cross-sectional survey. Afr J Reprod Health. 2013;17(1):103–13.
- MOH and RBC, "Rwanda Population-based HIV Impact Assessment. RPHIA 2018–2019," Report, no. September, pp. 1–232, 2020.
- 22. TACAIDS. Tanzania HIV Impact Survey (THIS) 2016-2017. 2018.
- 23. Verloo M, Roggeband C. Gender impact assessment: The development of a new instrument in the netherlands. Impact Assess. 1996;14(1):3–20.
- 24. Sia D, Onadja Y, Nandi A, Foro A, Brewer T. What lies behind gender inequalities in HIV/AIDS in sub-Saharan African countries: Evidence from Kenya, Lesotho and Tanzania. Health Policy Plan. 2014;29(7):938–49.
- Dougherty G, et al. Reaching the first 90: Improving inpatient pediatric provider-initiated HIV testing and counseling using a quality improvement collaborative strategy in Tanzania. J Assoc Nurses AIDS Care. 2019;30(6):682–90.
- De Anda S, et al. Predictors of First-Time and Repeat HIV Testing Among HIV-Positive Individuals in Kenya. J Acquir Immune Defic Syndr. 2020;85(4):399–407.
- Mugo PM, et al. Trends and predictors of HIV positivity and time since last test at voluntary counselling and testing encounters among adults in Kilifi, Kenya, 2006–2017. Wellcome Open Res. 2021;4:1–28.
- Odhiambo J, et al. Provider-initiated HIV testing and counselling for TB patients and suspects in Nairobi, Kenya. Int J Tuberc Lung Dis. 2008;12(3 SUPPL. 1):63–8.
- A. M. Kumar et al., "HIV testing among patients with presumptive Tuberculosis: How do we implement in a routine programmatic setting? Results of a large operational research from India," PLoS One, 2016; 1(5):.
- F. Hassen and N. Deyassa, "The relationship between sexual violence and human immunodeficiency virus (HIV) infection among women using voluntary counseling and testing services in South Wollo Zone, Ethiopia," BMC Res. Notes, 2013:6(1);

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

